Benign Conditions

Benign Prostatic Hyperplasia

Bladder Cancer

Female Urology

Genitourinary Cancers

Genomic Testing

Hormone Therapy

Kidney Cancer

Challenging Anatomy

Innovative Techniques

Laser Lithotripsy

PCNL Tech & Devices

Ureteroscopy Tech & Devices

Kidney Stones

Men's Health

Next-Generation Imaging

Voiding Dysfunction

OAB and Incontinence

Pediatrics

Controveries in Urologic Cancer

Drug Therapy

Prostate Cancer

Sexual Dysfunction

UTUC

Cosmetic Surgery

Urologic Surgery

Business

Practice Management

Malpractice Consult

Health Law & Policy

Media

Case-Based Peer Perspectives

Investigator Perspectives 

Medical World News

Podcasts

Urology Medical Perspectives

UTv Videos

Peer Exchange

Special Report

Virtual Tumor Board

Insights

Medcast

Peers & Perspectives

Conferences

Conference Listing

Conference Previews 

Conference Recaps

Publications

Urology Times Journal

Editorial Advisory Board

Urologists in Cancer Care

Supplements and Featured Publications

Clinical Forums Recaps

CME/CE

Resources

Begin Your Journey: Tackling Burnout

Live Events

Interactive Tools

Job Board

Partners

Subscribe

Articles

"The updated results from CLEAR trial confirming that the amount of tumor shrinkage correlates with prognosis through overall survival, PFS, as well as through IMDC prognostic scoring should add further weight to lenvatinib and pembrolizumab being a go-to standard of care in this setting," says Thomas E. Hutson, DO, PharmD.

CLEAR trial analyses reaffirm benefit of lenvatinib/pembrolizumab in aRCC

 is compliance officer and medical director of coding and reimbursement, United Urology Group and Chesapeake Urology, in Towson, Maryland.

"With the requirements for an E/M code as noted above, we agree with you that the supporting documentation, if appropriately documented, would support a level 3 outpatient visit for a visit regarding counseling for contraception or family planning," write Jonathan Rubenstein, MD, and Mark Painter.

Level of service for vasectomy prompts coding confusion

The designation is supported by preliminary data from the ongoing phase 1/2a SECuRE trial. 

FDA grants fast track designation to 67Cu-SAR-bisPSMA for mCRPC

According to ImmunityBio, shipments of rBCG are set to begin immediately via the EAP. 

FDA approves expanded access program to provide alternative source of BCG

Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do not sell my Personnal Information

Urology Times | News & Insights for Urologists & Health Professionals

Facebook

LinkedIn

Spotlight

Peers and Perspectives

Clinical

1rem

View

New Directions in the Treatment of Non-Muscle Invasive Bladder Cancer 

Video Series

The Mental Health Impact of NMIBC Treatment: Management With Your Patient 

Videos

Experts provide an overview of non-muscle invasive bladder cancer (NMIBC) and common procedures for diagnosis. 

A Comprehensive Overview of NMIBC

Experts discuss the variability of non-muscle invasive bladder cancer (NMIBC) in terms of staging and risk stratification and how they navigate these diagnoses with their patients. 

Standard of Care: Staging Considerations and Establishing Patient-Provider Relationships 

Experts discuss the evolving landscape of chemotherapy and immunotherapy options for patients with non-muscle invasive bladder cancer (NMIBC). 

Navigating Therapies for BCG-Unresponsive NMIBC: Immunotherapies and Chemotherapies

Experts discuss current trial data from several studies on non-muscle invasive bladder cancer (NMIBC).

New Horizons in NMIBC: Pipeline Innovations and Clinical Perspectives

Experts consider other pipeline treatments for non-muscle invasive bladder cancer (NMIBC), including new injectable options being explored.

Reducing Recurrence in NMIBC and Novel Treatment Approaches on the Horizon 

Experts discuss logistical considerations when providing the best treatment to patients with non-muscle invasive bladder cancer (NMIBC).

Practical Patient-Centered Logistics: Providing Care to Patients With NMIBC 

Experts discuss the mental impact of non-muscle invasive bladder cancer (NMIBC) treatment and approaches for developing a care network for those patients. 

Experts conclude their discussion on non-muscle invasive bladder cancer (NMIBC) highlighting practice considerations for today and the future. 

Navigating The Future of NMIBC Trails: Key Insights and Takeaways

The Mental Health Impact of NMIBC Treatment: Management With Your Patient

EP: 1.A Comprehensive Overview of NMIBC

EP: 2.Standard of Care: Staging Considerations and Establishing Patient-Provider Relationships

EP: 3.Navigating Therapies for BCG-Unresponsive NMIBC: Immunotherapies and Chemotherapies

EP: 4.New Horizons in NMIBC: Pipeline Innovations and Clinical Perspectives

EP: 5.Reducing Recurrence in NMIBC and Novel Treatment Approaches on the Horizon

EP: 6.Practical Patient-Centered Logistics: Providing Care to Patients With NMIBC

EP: 7.The Mental Health Impact of NMIBC Treatment: Management With Your Patient

EP: 8.Navigating The Future of NMIBC Trails: Key Insights and Takeaways